3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function - 16/06/19
pages | 7 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | AKBA inhibited Taxol-resistant cancer cell A2780/Taxol in vitro. |
• | AKBA inhibited A2780/Taxol xenograft tumor growth in vivo. |
• | AKBA reversed MDR proteins to exert its anti-cancer potency. |
Abstract |
Objective |
Recurrence of ovarian cancer is mainly due to multidrug resistance (MDR). 3-acetyl-11-keto-beta-boswellic acid (AKBA) could reverse the multidrug resistance in human ileocecal adenocarcinoma cells, but whether AKBA could modulate acquired MDR in ovarian cancer needs to be elucidated.
Methods |
The current study examined the effect of AKBA on ovarian cancer MDR using a Taxol resistant human ovarian cancer cell line A2780/Taxol. Cell proliferation, migration and invasion, the intracellular accumulation of Rhodamine 123 and expression of MDR proteins were studiedin vitro. Furthermore, the effect of AKBA on oncogenicity of A2780/Taxol cells in nude mice xenograft model was studied.
Results |
The results showed that apart from its cytostatic and apoptosis-induction effect, AKBA could restrain A2780/Taxol cell migration and invasion. In addition, AKBA improved the sensitivity of A2780/Taxol cells to Taxol apparently, and the reversal of MDR by AKBA was evident by increasing intracellular Rhodamine 123 in cells. Furthermore, the anti-cancer potential of AKBA was evidenced as that AKBA treatment significantly slowed tumor growth and decreased the expression of P-gp, LRP, BCRP and MRP.
Conclusion |
Above results indicated that AKBA might be a potential compound to reverse MDR in human ovarian cancer.
Le texte complet de cet article est disponible en PDF.Keywords : 3-acetyl-11-keto-beta-boswellic acid, Ovarian cancer, Multidrug resistance
Plan
Vol 116
Article 108992- août 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?